Superficial Femoral Artery Stenosis Clinical Trial
— CONTINUUMOfficial title:
CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")
Verified date | November 2019 |
Source | C. R. Bard |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of this study are to collect post-market confirmatory evidence of the safety and effectiveness of the Bard® LifeStent® Vascular Stent System and LifeStent® XL Vascular Stent System (together the "LifeStent® Vascular Stent System").
Status | Terminated |
Enrollment | 173 |
Est. completion date | September 19, 2018 |
Est. primary completion date | September 18, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: 1. The subject provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the Institutional Review Board (IRB) for the site. 2. Subject agrees to comply with the protocol-mandated follow-up procedures and visits. 3. The subject is = 21 years old. 4. Male or female subjects; female subjects of childbearing potential must have a negative urine pregnancy test at the time of screening. 5. The subject has lifestyle-limiting claudication or ischemic rest pain defined as: Rutherford Category 2-4. 6. The target lesion(s) has angiographic evidence of stenosis or restenosis = 50% or occlusion (by visual estimate) and is amenable to PTA with stenting. 7. The total target lesion(s) length must be = 240 mm. 8. The target vessel reference diameter is = 4.0 mm and = 6.5 mm (by visual estimate), and therefore appropriate for treatment with available stent diameters of 6.0 mm and 7.0 mm. Exclusion Criteria: 1. The subject is unable or unwilling to provide informed consent, or is unable or unwilling to conform to the study protocol follow-up procedures and visits. 2. The subject has claudication or critical limb ischemia described as Rutherford Category 1 (mild claudication), 5 (minor tissue loss) or 6 (major tissue loss. 3. The subject has multiple stenoses or occlusions > 240 mm. 4. The subject has a previous stent or stent graft located in the target vessel. 5. The subject has flow-limiting stenosis or occlusion of the inflow tract that cannot be adequately corrected (= 30% residual stenosis) prior to treatment of the target lesion(s). Investigator standard of care practices shall be utilized for treatment of inflow. 6. The subject has a known contraindication (including allergic reaction) to antiplatelet/anticoagulant medications, nickel, titanium, tantalum or sensitivity. 7. The subject has a known contraindication to contrast media that is not amenable to pretreatment with steroids or/and antihistamines. 8. The subject has a known history of bleeding diatheses or coagulopathy. 9. The subject has concomitant renal failure with a creatinine of > 2.5 mg/dL. 10. The subject is currently on dialysis or receiving systemic immunosuppressive therapy. 11. The subject has known concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus, septicemia or deep vein thrombosis at the time of the index procedure. 12. The subject is currently participating in an investigational drug or another investigational device study that has not completed the primary endpoint, or that clinically interferes with the study endpoints. Note: trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. 13. The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up. 14. The subject has extensive peripheral vascular disease, which in the opinion of the Investigator, would preclude safe insertion of an introducer sheath. 15. The target lesion(s) is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s). 16. There is angiographic evidence of unresolved thrombus at the target lesion(s) or within the target vessel that does not resolve with infusion of thrombolytics and/or mechanical thrombectomy (using an approved device) without adverse events/complications. 17. The subject has undergone any non-iliac percutaneous intervention(s) < 7 days prior to the index procedure. |
Country | Name | City | State |
---|---|---|---|
United States | Kentucky Heart Foundation | Ashland | Kentucky |
United States | Steward St. Elizabeth Medical Center of Boston Inc. | Boston | Massachusetts |
United States | The Cooper Health System | Camden | New Jersey |
United States | University Surgical Associates, LLC | Chattanooga | Tennessee |
United States | Loyola University Chicago | Chicago | Illinois |
United States | BCS Heart, LLP. | College Station | Texas |
United States | South Carolina Heart Center, P.A. | Columbia | South Carolina |
United States | Saint Vincent Consultants in Cardiovascular Diseases, LLC | Erie | Pennsylvania |
United States | McLeod Regional Medical Center | Florence | South Carolina |
United States | South Florida Medical Imaging, PA | Fort Lauderdale | Florida |
United States | Houston Center for Vascular Health | Houston | Texas |
United States | The Methodist Hospital Research Institute dba Houston Methodist Research Institute | Houston | Texas |
United States | The Huntington Heart Center | Huntington | New York |
United States | Heartland Vascular Center | Joliet | Illinois |
United States | University of Kansas Medical Center Research Institute, Inc. | Kansas City | Kansas |
United States | VA Greater Los Angeles Healthcare System | Los Angeles | California |
United States | Baptist Hospital of Miami | Miami | Florida |
United States | Mount Sinai Medical Center | Miami Beach | Florida |
United States | Aurora Medical Group | Milwaukee | Wisconsin |
United States | Cardiovascular Research of Northwest Indiana, LLC. | Munster | Indiana |
United States | Saint Peter's University Hospital | New Brunswick | New Jersey |
United States | Midwest Aortic Vascular Institute P.C | North Kansas City | Missouri |
United States | Trustees of the University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Allegheny-Singer Research Institute | Pittsburgh | Pennsylvania |
United States | Mission Cardiovascular Research Institute | Pleasanton | California |
United States | Sanford Research | Sioux Falls | South Dakota |
United States | Prairie Education and Research Cooperative (PERC) | Springfield | Illinois |
United States | PinnacleHealth Cardiovascular Institute | Wormleysburg | Pennsylvania |
United States | Metropolitan Hospital d/b/a Metro Health Hospital | Wyoming | Michigan |
Lead Sponsor | Collaborator |
---|---|
C. R. Bard |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Safety Endpoint: Freedom From Death at 30-days and 12-months Post-Index Procedure. | Primary safety endpoint defined as freedom from occurrence of death at 30-days and 12-months post-index procedure. | 30-days and 12-months | |
Primary | Primary Effectiveness Endpoint: Primary Target Lesion Patency (TLP) at Time of Procedure and 12-Months Post-Index Procedure | The primary effectiveness endpoint of the study, device success, collectively measured both acute and chronic effectiveness. Acute effectiveness is defined as successful delivery of the stent to the intended site with the post-deployment stent length being within 10% of the pre-deployment stent length. Chronic effectiveness is defined as Primary Target Lesion Patency (TLP) at 12-months post-index procedure, as measured by Duplex Ultrasound (DUS). |
At time of procedure (acute) and 12-months post-index procedure (Chronic) | |
Secondary | Freedom From Target Lesion Revascularization (TLR) and/or Target Vessel Revascularization (TVR) at 12-months Post-index Procedure. | Target Lesion Revascularization (TLR) is defined as the interval following the index procedure until the first revascularization procedure of the target lesion. Target Vessel Revascularization (TVR) is defined as the interval following the index procedure until the first revascularization procedure (e.g. PTA, stenting, surgical bypass, etc.) in the target vessel. | 12-months post-index procedure | |
Secondary | Primary Safety: Freedom From Death at 30-days and 12-months Post-Index Procedure for Target Lesion Lengths >160 mm Compared With LifeStent 200 mm. | • Primary Safety (freedom from occurrence of death at 30-days and 12-months post-index procedure) of the Target Lesion Lengths > 160 mm subgroup compared to the Target Lesions treated with the 200 mm LifeStent® subgroup. | 30-days and 12-months Post -Index Procedure | |
Secondary | Primary Effectiveness: Device Success at 12-Months Post-Index Procedure for Target Lesion Lengths > 160 mm Compared to LifeStent 200 mm. | Primary Effectiveness (Device Success) of Target Lesion Lengths > 160 mm subgroup compared to the Target Lesions treated with the 200 mm LifeStent® subgroup. | 12-months Post-Index Procedure | |
Secondary | Freedom From Fracture at 12 and 24-Months Post-Index Procedure | Freedom from Fracture (FFF) at 12- and 24-months post-index procedure. | 12- and 24-months post-index procedure | |
Secondary | Primary Target Lesion Patency (TLP) for Lesions > 160 mm at 12, 24, and 36 Months Post-Index Procedure | Primary Target Lesion Patency (TLP) - Sustained and Expanded - for Target Lesion Lengths > 160 mm at 12-, 24- and 36-months post-index procedure corresponding to Peak Systolic Ratio (PSR) values of < 2.0, <2.5, and < 3.0. | 12, 24, and 36 months Post Index Procedure | |
Secondary | Freedom From Target Lesion Revascularization (TLR) and/or Target Vessel Revascularization (TVR) at 12, 24, and 36-Months Post-Index Procedure for Target Lesion Lengths > 160 mm. | Freedom from Target Lesion Revascularization (TTR) and/or Target Vessel Revascularization (TRV) for Target Lesion Lengths > 160 mm at 12-, 24- and 36-months post-index procedure. | 12-, 24-, and 36-months post-index procedure | |
Secondary | Secondary Safety Endpoint: Freedom From Composite Adverse Events | Secondary Safety (Freedom from Composite Adverse Events) is defined as freedom from death (excluding 30-days and 12-months post-index procedure), stroke, myocardial infarction (MI), emergent surgical revascularization, significant distal embolization in target limb, target limb major amputation, and thrombosis of target vessel at 30-days and 12-, 24-, and 36-months post-index procedure. | 30-days and 12-, 24-, and 36-months post-index procedure | |
Secondary | Number of Stents Deployed With Acute Technical Success | Acute technical success is defined as successful deployment of the stent to the intended location. | Intra-procedure | |
Secondary | Number of Acute Lesion Success | Acute lesion success is defined as attainment of = 30% residual stenosis of the target lesion using any percutaneous method and/or non-investigational device (i.e., post-dilatation) based on angiographic data. | Intra-procedure | |
Secondary | Number of Procedures With Acute Success | Acute procedure success is defined as lesion success and no peri-procedural complications (death, stroke, MI, emergent surgical revascularization, significant distal embolization in target limb, and thrombosis of target vessel). | Intra-procedure | |
Secondary | Sustained Freedom From Target Lesion Reintervention (TLR) and/or Target Vessel Reintervention (TVR) at 24 and 36 Months Post-Index Procedure | Sustained Freedom from Target Lesion Reintervention (TLR) and/or Target Vessel Reintervention (TVR) at 24- and 36-months post-index procedure. | 24- and 36-months post-index procedure | |
Secondary | Number of Participants With Sustained Hemodynamic Success at 30-days, 12-, 24-, and 36-Months Post Index Procedure | Sustained hemodynamic success is defined as sustained improvement of Ankle-Brachial Index (ABI) from baseline value of = 0.15 at 30-days and 12-, 24-, and 36-months post-index procedure without the need for repeated Target Lesion Revascularization (TLR) in surviving subjects. | 30 days, 12-, 24-, and 36-months post-index procedure | |
Secondary | Number of Participants With Sustained Clinical Success at 30-Days, 12, 24, and 36- Months Post-Index Procedure | Sustained clinical success is defined as sustained cumulative improvement from baseline value of = 1 category according to Rutherford et al.12 at 30-days and 12-, 24-, and 36-months post-index procedure without the need for repeated TLR in surviving subjects. | 30-days and 12-, 24-, and 36-months post-index procedure | |
Secondary | Sustained Target Lesion Patency (TLP) at 24 and 36 Months Post-Index Procedure | Sustained Target Lesion Patency (TLP) was measured at 24- and 36-months post-index procedure corresponding to PSR < 2.5. | 24- and 36-months post-index procedure | |
Secondary | Expanded Target Lesion Patency (TLP) for Peak Systolic Velocity Ratio (PSR) < 3.0 at 12, 24, and 36 Months Post-Index Procedure | Expanded TLP was measured at 12-, 24- and 36-months post-index procedure corresponding to Peak Systolic Velocity Ratio (PSR) < 3.0. | 12, 24, and 36 months Post-Index Procedure | |
Secondary | Cumulative (Primary Assisted and Secondary) Target Lesion Patency (TLP) at 12, 24, and 36 Months Post-Index Procedure | Cumulative (primary-assisted and secondary) Target Lesion Patency (TLP) was measured at 12-, 24-, and 36-months post-index procedure corresponding to Peak Systolic Velocity Ratio (PSR) < 2.5, and PSR < 3.0. | 12, 24, and 36 Months Post-Index Procedure | |
Secondary | Change From Baseline in Walking Impairment Questionnaire (WIQ) Results at 30-Days and 12, 24 and 36-Months Post-Index Procedure | The Walking Impairment Questionnaire (WIQ) evaluation scale values range from 0 to 100, with 0 meaning inability to complete the specific task and 100 representing no difficulty in completing the task. A higher score (mean) represents an improvement in walking abilities compared to baseline measure. The results below represent, for each item measured (pain, walking distance, walking speed, and stair climbing), the mean difference between the score observed at Baseline and those observed at 30-days, 12-, 24-, and 36-months post-index procedure. | 30-days, and 12-, 24-, and 36-months post-index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03121430 -
Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion
|
N/A | |
Completed |
NCT01327950 -
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
|
N/A | |
Completed |
NCT05451485 -
VFI in Healthy Vessels
|
||
Not yet recruiting |
NCT04175197 -
LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries
|
||
Withdrawn |
NCT05079906 -
Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
|
N/A | |
Recruiting |
NCT04971772 -
SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries
|
||
Recruiting |
NCT04461496 -
Full Metall Jacket Multilevel Segment
|
N/A | |
Recruiting |
NCT04434586 -
Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions
|
N/A | |
Recruiting |
NCT05291247 -
Shockwave IVL + DES
|
||
Completed |
NCT01602159 -
Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)
|
N/A | |
Not yet recruiting |
NCT06410313 -
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
|
N/A | |
Recruiting |
NCT05132361 -
SELUTION4SFA Trial
|
N/A | |
Completed |
NCT01336101 -
Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent
|
N/A | |
Recruiting |
NCT06416644 -
The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)
|
N/A |